Rhone-poulenc Rorer S.a.

Bioprojet

Aventis Pharma S.a.

Rhone-poulenc Sante

Targacept, Inc.

Sun Pharma Advanced Research Company Limited

Bioproject

Bioprojet Pharma

Rhone-poulenc S.a.

Marc Capet

Jean-Charles Schwartz

Jeanne-Marie Lecomte

Philippe Robert

Jean-Dominique Bourzat

Nicolas Levoin

Claude Cotrel

Isabelle Berrebi-Bertrand

Franco Manfre

Xavier Ligneau

Claude Guyon

Gerard Roussel

Michel Cheve

Thierry Calmels

Olivier Labeeuw

Xavier Billot

Marie-Christine Dubroeucq

Denis Danvy

Jean-Paul Martin

Stéphane Krief

Gary Maurice Dull

Arielle Genevois-Borella

Jeffrey Daniel Schmitt

Patrick Mailliet

Norbert Dereu

Fabienne Sounigo-Thompson

Philippe Pitchen

Richard Labaudiniere

Serge Mignani

Rajamannar Thennati

Craig Harrison Miller

Jean-Luc Malleron

Jean Bouquerel

Daniel Achard

Augustin Hittinger

Alain Commercedillaon

Olivia Poupardin-Olivier

Bhavesh Mohanbhai Panchal

Jayraj Dilipbhai Aradhye

Biswajit Samanta

Ranjan Kumar Pal

Marie-Christine Dubroeuco

Serg Grisoni

Muthukumaran Natarajan Pillai

Isabelle Bertrand

Gilles Dutruc-Rosset

Hervé Bouchard

Herv&eacute; Bouchard

Alain Commer&ccedil;on

Thomas Caulfield

Gilles Tiraboschi

Sandeep Pankajbhai Pathak

Japan Nitinkumar Desai

Morgan Pauchet

Michel Joannic

G Erard Roussel

Jignesh Kantilal Jivani

G&eacute;rard Coquerel

Dijixa Chandubhai Rana

Kaushik Dhanjubhai Prajapati

Marcel Morvan

Marie-No&euml;lle Petit

Rajamannar c/o Sun Pharma Advanced Research Centre Thennati

Biswajit c/o Sun Pharma Advanced Research Centre Samanta

Ranjan Kumar c/o Sun Pharma Advanced Research Centre Pal

Isabelle Berrebi Bertrand

Jayraj D Aradhye

Bhavesh M Panchal

The present disclosure relates generally to a new crystalline form (i.e., polymorph) of pitolisant hydrochloride (Form II), pharmaceutical compositions comprising Form II, dosage forms comprising Form II, and methods of treating a disease or disorder with Form II, or with a pharmaceutical composition or dosage form comprising Form II.

Polymorph form of pitolisant hydrochloride

The present application concerns novel benzimidazole enantiomeric derivatives, their process of preparation and their therapeutical uses as dual H1 and H4 receptor ligands.

Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands

Novel benzimidazole enantiomeric derivatives, their process of preparation and their therapeutical uses as dual H1 and H4 receptor ligands are disclosed.

The present invention concerns new therapeutical uses, including low dosage administration of the highly potent H3-ligand: (3S)-4-{4-[3-(3-methylpiperidin-1-yl)propoxy]phenyl}pyridine 1-oxide.

Therapeutical use of H3-ligands

The present invention concerns the tetrahydrate form of the compound: (3S)-4-{4-[3-(3-methylpiperidin-1-yl)propoxy]phenyl}pyridine 1-oxide, dihydrochloride, its process of preparation and therapeutical uses thereof.

Tetrahydrate of H3 ligand, its process of preparation and pharmaceutical compositions comprising the same

The present invention relates to novel compounds acting as agonists at S1P (sphingosine-1-phosphate) receptors, compositions containing these compounds, use of these compounds in medicine and their process of preparation. 

Piperidinyl monocarboxylic acids as S1P1 receptor agonists

The present patent application concerns new ligands of the H4-receptor, their process of preparation and their therapeutic use.

6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepines derivatives as histamine H4 receptor ligands

The present invention concerns novel (aza)benzhydryl ether derivatives which exhibit H4-receptor binding activity. The present invention also concerns their process of preparation and their therapeutical uses.

(Aza)benzhydryl ether derivatives, their process of preparation and their use as H4-receptor ligands for therapeutical applications

Benzazole derivatives as histamine H4 receptor ligands

The present invention relates to new compounds of formula (I) possessing agonistic activity at sphingosine-1-phosphate (S1P) receptors, their process of preparation and their use as immunosuppressive agents. The invention is also directed to pharmaceutical compositions containing these compounds and use of these compounds for treatment/prevention of immune mediated diseases and conditions or inflammatory diseases and conditions.

Dicarboxylic acid derivatives as S1P1 receptor agonists

The present patent application concerns new ligands of the H4-receptor of formula (I), their process of preparation and their therapeutic use. 

The invention relates to compounds of the general formula (I): to the process for preparing them, and to the use thereof as a therapeutic agent. 

[object Object]

Novel vinylazacycloalkane compounds of Formula (I) are disclosed. The compounds are ligands of various nAChRs. The compounds and their pharmaceutically acceptable salts can be used to prepare pharmaceutical compositions and/or medicaments intended to prevent or treat disorders associated with dysfunction of nAChRs, especially within the central nervous system or the gastrointestinal system. Examples of types of disorders that can be treated include neurodegenerative disorders, including central nervous system disorders such as Alzheimer's disease, cognitive disorders, motor disorders such as Parkinson's disease, drug addiction, behavioral disorders and inflammatory disorders within the gastrointestinal system. The compounds can also serve as analgesics in the treatment of acute, chronic or recurrent pain.

Arylvinylazacycloalkane compounds and methods of preparation and use thereof

The present patent application concerns compounds of formula (I) with R1 and R2 taken together with the nitrogen atom to which they are attached, form a mono or bicyclic saturated nitrogen-containing ring; their preparation and their use as a H3 receptor ligand for treating e.g. CNS disorders like Alzheimer's disease.

Histamine H3-receptor ligands and their therapeutic applications

Growing community of inventors

Melesse, France

Marc Capet